Publicaciones en colaboración con investigadores/as de Centre Hospitalier Regional et Universitaire de Lille (88)

2024

  1. EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 51, Núm. 7, pp. 1891-1908

  2. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

    The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227

  3. Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

    Blood

  4. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  5. Multiomics of the intestine-liver-adipose axis in multiple studies unveils a consistent link of the gut microbiota and the antiviral response with systemic glucose metabolism

    Gut

  6. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235

  7. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595

  8. Transplantation for myelofibrosis patients in the ruxolitinib era: a registry study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire

    Bone Marrow Transplantation, Vol. 59, Núm. 7, pp. 965-973